The world of cancer research is constantly evolving, and sometimes, a simple Twitter thread can spark a fascinating revelation. Rahul Banerjee, a renowned assistant professor, shared a thread that caught the attention of many, shedding light on the previously unknown aspects of myeloma treatment resistance.
But here's where it gets intriguing: Banerjee highlights a post by Nizar Jacques Bahlis, which delves into the complexities of GPRC5D therapy resistance in myeloma. The original research, led by Dr. Holly Lee, uncovers a multitude of resistance mechanisms to anti-GPRC5D TCE (T-cell engagers) in multiple myeloma patients.
The study reveals that while GPRC5D-targeted TCEs show promising results in relapsed/refractory multiple myeloma (RRMM), most patients eventually relapse. By analyzing 21 MM patient samples, the researchers identified various genetic and epigenetic mechanisms leading to relapse, all converging on GPRC5D escape. This escape mechanism suggests a strong evolutionary response to TCE therapy.
The research team employed a multi-omic approach, including WGS, scRNA/ATAC-seq, flow cytometry, imaging, and functional assays, to understand the intricate details of tumor adaptation. They discovered that GPRC5D antigen escape occurred in 61.9% of relapses, with alterations through SNVs/indels, CN loss, focal/large CN loss, or epigenetic silencing. These mechanisms either led to the loss of surface antigen or modified the talquetamab binding epitope, hindering treatment effectiveness.
Further analysis revealed two primary resistance mechanisms. Controversially, Mechanism #1 involves ER to membrane trafficking defects, where mutations trap GPRC5D in the ER, reducing its surface expression. Mechanism #2 is even more intriguing; certain GPRC5D mutations preserve surface expression but alter talquetamab binding, leading to complete resistance when combined with truncating mutations.
The study also emphasizes the importance of dosing, as higher concentrations of talquetamab can partially restore binding and cytotoxicity against specific GPRC5D mutations. Additionally, it highlights the sensitivity of certain GPRC5D mutants to dual-epitope targeting TCEs, even when surface antigen expression is below the detection limit of conventional flow cytometry.
And this is the part most people miss: Epigenetic silencing of GPRC5D in B-cell like t(11;14) MM, coupled with frameshift mutations, contributes to talquetamab resistance. This finding underscores the complexity of resistance mechanisms and the need for comprehensive profiling.
In summary, this research provides valuable insights into the multi-modal nature of resistance, the importance of adequate dosing, and the potential of dual-epitope targeting TCEs in overcoming certain resistant mutations. It also highlights the role of epigenetic silencing in B-cell myeloma, opening up new avenues for further investigation and discussion.
